Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.

Leukemia - 1 Feb 2008

Kaderi M A, Norberg M, Murray F, Merup M, Sundström C, Roos G, Aleskog A, Karlsson K, Axelsson T, Tobin G, Rosenquist R

Abstract excerpt

The (-938C>A) polymorphism in the promoter region of the BCL-2 gene was recently associated with inferior time to treatment and overall survival in B-cell chronic lymphocytic leukemia (CLL) patients displaying the -938A/A genotype and may thus serve as an unfavorable genetic marker in CLL. Furthermore, the -938A/A genotype was associated with increased expression of Bcl-2. To investigate this further, we analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Genes, bcl-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Epidemiology

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Survival Analysis

Share to Treatment Outcome

Source

Identifiers

PMID: 18046447
DOI: 10.1038/sj.leu.2405042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.PMID 18046447Read ↗

Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.Semantic proximity Read ↗

BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia.Semantic proximity Read ↗

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.Semantic proximity Read ↗

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.Semantic proximity Read ↗

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.Semantic proximity Read ↗

The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.Semantic proximity Read ↗

Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.Semantic proximity Read ↗

BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.Semantic proximity Read ↗

Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.